CyberKnife treatment delivers full local control for uveal melanoma at ISRS2026, with favorable safety profile

CyberKnife treatment delivers full local control for uveal melanoma at ISRS2026, with favorable safety profile
Accuray CyberKnife controls melanoma

Accuray reported that in a retrospective analysis presented at ISRS2026, all 68 uveal melanoma patients treated with CyberKnife achieved local tumor control at a mean follow-up of 46.5 months.

The findings, shared from CDI Milan in Italy, describe the treatment as safe, minimally invasive, and well tolerated. This study highlights the potential efficacy of CyberKnife radiosurgery for managing uveal melanoma, an ocular cancer with limited treatment options. Ongoing research will further clarify long-term outcomes and broader applicability.

At ESTRO26 in Milan, Accuray previously unveiled PRO-FAST, a single-day prostate radiotherapy protocol using CyberKnife, according to company disclosures. The meeting also featured new pediatric radiotherapy developments with the Radixact platform during a presentation by Dr. Liam Herbert. These updates reflect Accuray's ongoing efforts to introduce new protocols and expand clinical evidence for its radiotherapy systems.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.